Breckenridge Pharmaceutical, Inc. Signs Multi-Product Agreement with Sam Chun Dang Pharm. Co. Ltd.

Friday, June 30, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

BOCA RATON, Fla., June 30, 2017 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today that it has entered

into a multi-product agreement with Sam Chun Dang Pharm. Co. Ltd. (SCD), based in Seoul, Korea, under which Breckenridge and SCD expect to develop and commercialize at least seven ANDAs.
 Under the terms of the agreement, SCD will develop, manufacture and supply the products exclusively for Breckenridge for the U.S. market and Breckenridge will market and distribute the products in its label.  This multi-product agreement represents the first foray for both companies having products developed and manufactured in South Korea for the U.S. market.

This agreement contemplates filing ANDAs for at least six ophthalmic products and one otic product, beginning in the first quarter of 2018.  The total addressable IMS market value for this portfolio is $2.4 billion USD.  

This selection of products also contributes to Breckenridge's Paragraph IV portfolio.  Breckenridge currently has twenty-six (26) ANDAs filed and pending with FDA that contain Paragraph IV patent challenges, and intends to continue that trend in the next several years, focusing on niche and first-to-file Paragraph IV opportunities with certain barriers to entry.

About Breckenridge:Breckenridge Pharmaceutical, Inc. is a privately-held own-label distributor that performs pharmaceutical marketing, research and development, as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectable products. www.bpirx.com

About Sam Chun Dang Pharm. Co. Ltd.:SCD is a privately-held manufacturer based in Seoul, Korea that develops and manufactures ophthalmic solutions, solid orals, nasal solutions, and ampules for a wide range of therapeutic classes.   Founded in 1943, SCD exports its products to Asia, the Middle East, North America, and throughout Latin America. 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/breckenridge-pharmaceutical-inc-signs-multi-product-agreement-with-sam-chun-dang-pharm-co-ltd-300481517.html

SOURCE Breckenridge Pharmaceutical, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook